{
  "@context": "https://schema.org",
  "@graph": [
    {
      "@type": "Organization",
      "@id": "http://www.partnertx.com/#organization",
      "name": "Partner Therapeutics",
      "url": "http://www.partnertx.com/",
      "description": "The company believes in delivering products and supporting medical teams with the purpose of achieving superior outcomes for patients and their families. Our Purpose Company News Research Latest News Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO) ... Partner Therapeutics Announces FDA Approval of BIZENGRI® (Zenocutuzumab-zbco) for NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt of FDA Commissioner’s National Priority Voucher ..."
    },
    {
      "@type": "WebPage",
      "@id": "https://asg.websdocs.com/directory/business/partner-therapeutics#asg",
      "name": "Partner Therapeutics ASG Directory Profile",
      "url": "https://asg.websdocs.com/directory/business/partner-therapeutics",
      "isPartOf": {
        "@id": "http://www.partnertx.com/#organization"
      },
      "description": "Static AI-readable public business profile published by the WebsDocs ASG Directory."
    }
  ]
}